Advertisements


How Aslan Pharma Is Capitalizing on Its Huge Atopic Dermatitis Success

Aslan Pharmaceuticals has been on a roller coaster for the past two weeks. Now the stock is coming back to earth, with the company announcing that it will be capitalizing on these gains with a........»»

Category: blogSource: 247wallstDec 3rd, 2019

Why This Atopic Dermatitis Study Was So Well Received

Aslan Pharmaceuticals shares jumped on Monday after the firm announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose study of its treatment of........»»

Category: blogSource: 247wallstDec 2nd, 2019

Aslan Pharmaceuticals completes Phase 1 study for ASLAN004 in atopic dermatitis

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 4th, 2019

Why Dermira"s Shares Are Doubling Today

Great clinical results for its experimental atopic dermatitis drug provided a huge catalyst for Dermira......»»

Category: topSource: foxnewsMar 18th, 2019

How Marinus Pharma Is Capitalizing on Its Depression Study Success

Marinus shares backed off on Wednesday when the firm announced that it would be conducting a secondary offering. The company is capitalizing on its success earlier this week when it announced........»»

Category: blogSource: 247wallstDec 12th, 2018

Dermira soars after AnaptysBio drug fails in atopic dermatitis trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 8th, 2019

Dermir rallies after AnaptysBio drug fails in atopic dermatitis trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 8th, 2019

AnaptysBio can rally 100% on positive atopic dermatitis data, says Jefferies

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 4th, 2019

Dermira Moves Forward With Atopic Dermatitis Drug As It Looks To Take On A Major Competitor

Dermira Moves Forward With Atopic Dermatitis Drug As It Looks To Take On A Major Competitor.....»»

Category: topSource: seekingalphaNov 1st, 2019

Huge Up, Tiny Down

FEEDOver the course of 2019, the two principal success stori.....»»

Category: blogSource: slopeofhopeOct 31st, 2019

Galapagos, MorphoSys announce end of MOR106 program in atopic dermatitis

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 29th, 2019

MorphoSys ends clinical development of MOR106 in atopic dermatitis

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 29th, 2019

Triangle drugmaker plans merger with Israeli pharma

The merger of a Triangle public drugmaker and an Israeli outfit led by former-Salix executives could have huge potential for Raleigh and its gastrointestinal candidates......»»

Category: topSource: bizjournalsOct 8th, 2019

Piper Jaffray backs Overweight rating on Aslan Pharma after JV creation

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 30th, 2019

Sanofi Lobs A Huge Liability Back To Lexicon Pharma With Deal Breakup; Lexicon Is Now Out Of Options And Nearly Out Of Cash

Sanofi Lobs A Huge Liability Back To Lexicon Pharma With Deal Breakup; Lexicon Is Now Out Of Options And Nearly Out Of Cash.....»»

Category: topSource: seekingalphaSep 30th, 2019

Good News for Teens Suffering Atopic Dermatitis

Pfizer has announced positive top-line results from a second Phase 3 pivotal study evaluating abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis......»»

Category: blogSource: 247wallstSep 27th, 2019

Pfizer reports positive results from second late-stage trial of treatment for atopic dermatitis

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchSep 27th, 2019

Local companies retain success from Made In Hawaii Fest: Slideshow

The Made in Hawaii Festival kicked off Friday at the Neal Blaisdell Arena, and the three day event features more than 530 booths, a huge leap from the 61 booths it had in its first year 25 years ago. Click through the gallery above to see some of the .....»»

Category: topSource: bizjournalsAug 16th, 2019

MarketWatch First Take: AMD has built Rome, but it will take much more than a day to know if it’s a winner

It took much more than a day for Advanced Micro Devices Inc. to build Rome, and capitalizing on it will take even longer, but the potential payoff is huge......»»

Category: topSource: marketwatchAug 7th, 2019

The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was a huge casualty a.....»»

Category: earningsSource: benzingaAug 3rd, 2019

Pfizer"s Eucrisa Proves Safety in Kids with Atopic Dermatitis

Pfizer's (PFE) Eucrisa ointment is found safe in a late-stage label expansion study for treating mild to moderate atopic dermatitis .....»»

Category: dealsSource: nytJul 2nd, 2019